 |
6 Diseases |  |
125 Trials |
|
125 Trials |  |
2571 News |  |
| «12...22232425262728293031323334» |
- || CA102N / Holy Stone Healthcare
Trial initiation date, Monotherapy, Metastases: First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Feb 25, 2019
P1, N=33, Not yet recruiting, Sponsor: Holy Stone Healthcare Co., Ltd
Initiation date: Nov 2018 --> Mar 2019
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Stivarga (regorafenib) / Bayer
New P2 trial, Circulating tumor DNA, Metastases: TACT-D: Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 18, 2019
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
- || Lonsurf (trifluridine/tipiracil) / Otsuka, futuximab/modotuximab (S95026) / Servier
Enrollment change, Trial withdrawal, Metastases: Sym004 Versus TAS-102 in Patients With mCRC (clinicaltrials.gov) - Feb 4, 2019
P3, N=0, Withdrawn, Sponsor: Symphogen A/S
Initiation date: Nov 2018 --> Mar 2019 N=550 --> 0 | Not yet recruiting --> Withdrawn
- || Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open, Checkpoint inhibition, Metastases: A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer (clinicaltrials.gov) - Feb 1, 2019
P2, N=22, Recruiting, Sponsor: Rahul Parikh
N=550 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- Lonsurf (trifluridine/tipiracil) / Otsuka
Trial primary completion date, Metastases: TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) (clinicaltrials.gov) - Jan 22, 2019
P2, N=4, Active, not recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2020 --> Dec 2018
- ||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
New P1 trial, Combination therapy: Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE (clinicaltrials.gov) - Jan 22, 2019
P1, N=57, Not yet recruiting, Sponsor: PharmaEngine
- || murlentamab (GM102) / Exelixis
New P2a trial, Combination therapy, Metastases: Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers (clinicaltrials.gov) - Jan 9, 2019
P2a, N=30, Recruiting, Sponsor: GamaMabs Pharma
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion, Metastases: Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies (clinicaltrials.gov) - Dec 21, 2018
P2/3, N=26, Completed, Sponsor: Institut de Recherches Internationales Servier
Trial primary completion date: Jul 2020 --> Dec 2018 Active, not recruiting --> Completed
- ||||| Lonsurf (trifluridine/tipiracil) / Otsuka, Cyramza (ramucirumab) / Eli Lilly
New P2b trial, Combination therapy, Monotherapy, Metastases: RAMTAS: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Dec 21, 2018
P2b, N=144, Not yet recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
- ||| Lonsurf (trifluridine/tipiracil) / Otsuka, Cyramza (ramucirumab) / Eli Lilly
Enrollment open, Trial initiation date, Combination therapy, Monotherapy, Metastases: RAMTAS: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Dec 21, 2018
P2b, N=144, Recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Active, not recruiting --> Completed Initiation date: Aug 2018 --> Dec 2018 | Not yet recruiting --> Recruiting
- ||| Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment closed, Enrollment change, Metastases: TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) (clinicaltrials.gov) - Dec 12, 2018
P2, N=4, Active, not recruiting, Sponsor: University of Florida
Initiation date: Aug 2018 --> Dec 2018 | Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=34 --> 4
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Metastases: Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies (clinicaltrials.gov) - Dec 11, 2018
P2/3, N=26, Active, not recruiting, Sponsor: Institut de Recherches Internationales Servier
Recruiting --> Active, not recruiting | N=34 --> 4 Trial completion date: Sep 2018 --> Dec 2018
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Cyramza (ramucirumab) / Eli Lilly
Enrollment open: TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Dec 3, 2018
P2, N=25, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Sep 2018 --> Dec 2018 Not yet recruiting --> Recruiting
- || Lonsurf (trifluridine/tipiracil) / Otsuka
New P2 trial, Checkpoint inhibition, Metastases: A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer (clinicaltrials.gov) - Dec 3, 2018
P2, N=22, Not yet recruiting, Sponsor: Rahul Parikh
- | Lonsurf (trifluridine/tipiracil) / Otsuka, futuximab/modotuximab (S95026) / Servier
New P3 trial, Metastases: Sym004 Versus TAS-102 in Patients With mCRC (clinicaltrials.gov) - Oct 22, 2018
P3, N=550, Not yet recruiting, Sponsor: Symphogen A/S
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial suspension, Metastases: TAS-102 in Treating Advanced Biliary Tract Cancers (clinicaltrials.gov) - Oct 22, 2018
P2, N=28, Suspended, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Suspended
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion, Trial completion date, Trial primary completion date, Metastases: TAGS: Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer (clinicaltrials.gov) - Oct 1, 2018
P3, N=506, Completed, Sponsor: Taiho Oncology, Inc.
Recruiting --> Suspended Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Dec 2017 | Trial primary completion date: Jun 2018 --> Dec 2017
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Cyramza (ramucirumab) / Eli Lilly
New P2 trial: TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Sep 27, 2018
P2, N=25, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm
Clinical, P3 data, Journal: The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. (Pubmed Central) - Sep 23, 2018
P3
Trifluridine/tipiracil was effective in all subgroups, regardless of age, geographical origin or KRAS status. This trial is registered with ClinicalTrials.gov: NCT01607957.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion, Trial completion date: A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC (clinicaltrials.gov) - Sep 19, 2018
P2, N=35, Completed, Sponsor: Taiho Oncology, Inc.
This trial is registered with ClinicalTrials.gov: NCT01607957. Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Nov 2017
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial primary completion date, Metastases: A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment (clinicaltrials.gov) - Sep 18, 2018
P1, N=48, Recruiting, Sponsor: Taiho Oncology, Inc.
Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Nov 2017 Trial completion date: Nov 2017 --> Jul 2019 | Trial primary completion date: Nov 2017 --> Jul 2019
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: LUPIN: Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 17, 2018
P1, N=94, Recruiting, Sponsor: Institut de Recherches Internationales Servier
Trial completion date: Nov 2017 --> Jul 2019 | Trial primary completion date: Nov 2017 --> Jul 2019 Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019
- | Trial primary completion date, Metastases: Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 10, 2018
P2, N=108, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019 Trial primary completion date: Sep 2018 --> Sep 2019
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Stivarga (regorafenib) / Bayer
Journal: Chemotherapy re-challenge response rate in metastatic colorectal cancer. (Pubmed Central) - Aug 30, 2018
Oxaliplatin or irinotecan-based re-challenge should be considered as a third or fourth line treatment option in select patients with mCRC. CBR and especially TTP compare favorably to approved third line therapies such as regorafenib or trifluridine-tipiracil.
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Trial termination, Metastases: ALEXANDRIA: Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 7, 2018
P2, N=4, Terminated, Sponsor: Georgetown University
CBR and especially TTP compare favorably to approved third line therapies such as regorafenib or trifluridine-tipiracil. Completed --> Terminated; Principal investigator left the institution
- | CA102N / Holy Stone Healthcare
New P1 trial, Monotherapy, Metastases: First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 6, 2018
P1, N=33, Not yet recruiting, Sponsor: Holy Stone Healthcare Co., Ltd
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open, Surgery, Metastases: TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 2, 2018
P1, N=24, Recruiting, Sponsor: Mayo Clinic
Completed --> Terminated; Principal investigator left the institution Suspended --> Recruiting
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm
Clinical, Journal: Integrated safety summary for trifluridine/tipiracil (TAS-102). (Pubmed Central) - May 12, 2018
There was a low rate of discontinuations, SAEs, and fatal AEs. This analysis confirms the safety profile observed in RECOURSE.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Metastases: TASCO1: A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy (clinicaltrials.gov) - Apr 25, 2018
P2, N=150, Active, not recruiting, Sponsor: Institut de Recherches Internationales Servier
This analysis confirms the safety profile observed in RECOURSE. Trial completion date: Apr 2019 --> Oct 2019
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Metastases: Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies (clinicaltrials.gov) - Apr 13, 2018
P2/3, N=26, Active, not recruiting, Sponsor: Institut de Recherches Internationales Servier
Trial completion date: Apr 2019 --> Oct 2019 Trial completion date: May 2018 --> Sep 2018
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial primary completion date, Metastases: TASCO1: A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy (clinicaltrials.gov) - Apr 12, 2018
P2, N=150, Active, not recruiting, Sponsor: Institut de Recherches Internationales Servier
Trial completion date: May 2018 --> Sep 2018 Trial primary completion date: Apr 2019 --> Jan 2018
- Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open, Combination therapy, Metastases: Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs (clinicaltrials.gov) - Apr 10, 2018
P1, N=33, Recruiting, Sponsor: University of Wisconsin, Madison
Trial primary completion date: Apr 2019 --> Jan 2018 Suspended --> Recruiting
- |||| Vectibix (panitumumab) / Amgen
Trial completion: APOLLON: A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer (clinicaltrials.gov) - Apr 5, 2018
P1/2, N=56, Completed, Sponsor: Takeda
Suspended --> Recruiting Active, not recruiting --> Completed
- Lonsurf (trifluridine/tipiracil) / Otsuka
Trial suspension, Combination therapy, Metastases: Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs (clinicaltrials.gov) - Mar 29, 2018
P1, N=33, Suspended, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed Recruiting --> Suspended
- | Clinical, Review, Journal: A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases. (Pubmed Central) - Mar 28, 2018
In patients with liver-only or liver-dominant disease, direct chemotherapy to the liver such as hepatic artery infusional (HAI) chemotherapy and radioembolization (yttrium-90 (Y90)) should be considered. Due to the difficulty of HAI therapy post Y90 for technical reasons, we recommend HAI therapy prior to Y90.
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Mekinist (trametinib) / Novartis, BeiGene
Enrollment open, Combination therapy, Surgery, Metastases: Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 26, 2018
P1, N=26, Recruiting, Sponsor: City of Hope Medical Center
Due to the difficulty of HAI therapy post Y90 for technical reasons, we recommend HAI therapy prior to Y90. Not yet recruiting --> Recruiting
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial primary completion date, Metastases: Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies (clinicaltrials.gov) - Mar 22, 2018
P2/3, N=26, Active, not recruiting, Sponsor: Institut de Recherches Internationales Servier
Not yet recruiting --> Recruiting Trial primary completion date: May 2018 --> Dec 2017
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Review, Journal: Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102). (Pubmed Central) - Mar 9, 2018
The most frequent adverse events reported in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in the phase III RECOURSE trial were myelosuppression, nausea/vomiting, diarrhea, decreased appetite, and fatigue. In this review we aim to provide clinicians with practical recommendations for facilitating patient adherence to oral chemotherapy, managing trifluridine/tipiracil dosing, and address the most common adverse events in patients who receive trifluridine/tipiracil therapy.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, Journal: Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. (Pubmed Central) - Mar 4, 2018
In the validation cohort, patients having ATM rs609429 with any G allele showed longer OS and PFS; the G/A variant in XRCC3 rs861539 showed longer OS, though without statistical significance. Genetic variants in the HR pathway may predict clinical outcome in mCRC patients receiving TAS-102.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial primary completion date, Metastases: Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies (clinicaltrials.gov) - Feb 27, 2018
P2/3, N=26, Active, not recruiting, Sponsor: Institut de Recherches Internationales Servier
Genetic variants in the HR pathway may predict clinical outcome in mCRC patients receiving TAS-102. Trial primary completion date: Dec 2017 --> May 2018 | Trial completion date: Dec 2017 --> May 2018
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm
Clinical, P1 data, Journal: A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil. (Pubmed Central) - Feb 25, 2018
Although the lower limit of the 90%CI for the geometric mean ratio of FTD Cmax was slightly lower than 0.80, the bioavailability of the TAS-102 tablet is considered clinically similar to that of a TAS-102 oral solution. TAS-102 was well tolerated in this population of patients with advanced solid tumors.
- ||||||| Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion, Trial primary completion date, Metastases: Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia (clinicaltrials.gov) - Feb 7, 2018
P3, N=406, Completed, Sponsor: Taiho Pharmaceutical Co., Ltd.
TAS-102 was well tolerated in this population of patients with advanced solid tumors. Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Feb 2016
- |||| Lonsurf (trifluridine/tipiracil) / Otsuka, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: TAS102 in Combination With NAL-IRI in Advanced GI Cancers (clinicaltrials.gov) - Feb 5, 2018
P1/2, N=64, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Feb 2016 Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Jan 2018 | Trial primary completion date: Nov 2020 --> Feb 2020 | Trial completion date: Nov 2020 --> Feb 2020
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Mekinist (trametinib) / Novartis, BeiGene
Trial initiation date, Trial primary completion date, Combination therapy, Surgery, Metastases: Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 17, 2018
P1, N=26, Not yet recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Jan 2018 | Trial primary completion date: Nov 2020 --> Feb 2020 | Trial completion date: Nov 2020 --> Feb 2020 Initiation date: Dec 2017 --> Jun 2018 | Trial primary completion date: Jun 2019 --> Dec 2019
- ||||| Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment closed, Metastases: TAGS: Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 8, 2018
P3, N=506, Active, not recruiting, Sponsor: Taiho Oncology, Inc.
Initiation date: Dec 2017 --> Jun 2018 | Trial primary completion date: Jun 2019 --> Dec 2019 Recruiting --> Active, not recruiting
- |||| Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open: Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jan 4, 2018
P1/2, N=56, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Lonsurf (trifluridine/tipiracil) / Otsuka
New P2 trial, Metastases: TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) (clinicaltrials.gov) - Dec 19, 2017
P2, N=34, Recruiting, Sponsor: University of Florida
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment change, Metastases: TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003) (clinicaltrials.gov) - Dec 18, 2017
P2, N=50, Recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting N=33 --> 50
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm
Journal: A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. (Pubmed Central) - Dec 16, 2017
Plasma concentrations of the major metabolite of trifluridine were lower following the administration of trifluridine/tipiracil vs trifluridine alone. Conclusion Tipiracil administered in combination with trifluridine significantly increased exposure to trifluridine compared with trifluridine alone.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment open, Surgery, Metastases: TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 13, 2017
P1, N=24, Recruiting, Sponsor: Mayo Clinic
Conclusion Tipiracil administered in combination with trifluridine significantly increased exposure to trifluridine compared with trifluridine alone. Not yet recruiting --> Recruiting